RxDoctor Payments Data

Stuart Milan

Psychiatric/Mental Health · Jackson, MSNPI 1689766958

Payments from drug & device makers

$2,440in general payments, 2019–2025

Across 121 payments — averaging $20.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$944
  • Vanda Pharmaceuticals Inc.$417
  • Otsuka America Pharmaceutical, Inc.$265
  • Axsome Therapeutics, Inc.$242
  • Indivior Inc.$238
  • Johnson & Johnson$91
  • plus $242 from 6 others

What the payments were for

  • Food & beverage$2,440100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,440 in reported general payments places this provider in the 75th percentile of 486 psychiatric/mental health providers in Mississippi.

See all psychiatric/mental health providers in Mississippi

Medicare billing

Part B allowed, 2024
$6,891
Medicare patients
25
Services billed
84

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl77$111,945
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl302$41,947
ZubsolvBuprenorphine Hcl/Naloxone Hcl24$10,822
SuboxoneBuprenorphine Hcl/Naloxone Hcl13$6,375
BelbucaBuprenorphine Hcl11$5,992
Desvenlafaxine Succinate ErDesvenlafaxine Succinate59$2,147
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine24$1,591
Quetiapine Fumarate145$1,360
Ramelteon12$1,251
Duloxetine Hcl84$1,213
Buspirone Hcl76$1,155
Clonazepam119$1,014
Atomoxetine Hcl16$996
Gabapentin100$972
Aripiprazole68$940

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$944$111,94577 claims
Indivior Inc.Suboxone$238$6,37513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 486 psychiatric/mental health providers in Mississippi.

Other psychiatric/mental health in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →